Erlotinib versus gefitinib for brain metastases in Asian patients with exon 19 EGFR-mutant lung adenocarcinoma: a retrospective, multicenter study

Table 1 Baseline characteristics between groups

Variable	Erlotinib (n = 112)	Gefitinib (n = 115)	p - value
Age at onset (years)	58.4 ± 19.52	58.5 ± 20.13	0.212^a
Sex			0.846^b
Female	85	86
Male	27	29
Smoking status			0.644^c
Never a smoker	67	65
Former smokers	23	26
Current smokers	22	24
Largest size of brain metastasis			0.841^c
≤ 10 mm	26	28
> 10 mm	86	87
Number of brain metastasis			0.764^c
≤ 3	65	69
> 3	47	46
ECOG performance status			0.838^c
0	33	35
1	46	43
2	25	27
3	8	10
Neurological symptoms before the initiation of TKIs			0.352^c
Nausea	6	5
Headache	3	3
Depressed level of consciousness	2	2
Gait disturbance	1	0
Muscle weakness	0	1
Dizziness	1	1
Urinary retention	1	1
Cognitive disturbance	2	2
Memory impairment	1	2
Blurred vision	2	1

^aAnalysed using independent-samples t-test. ^bAnalysed using chi-squared test. ^cAnalysed using the Mann-Whitney test. ECOG Eastern Cooperative Oncology Group. TKIs Tyrosine kinase inhibitors

ISSN: 1471-2466